

Comments on “Smoking patterns and outcomes of severe SARS-CoV-2 infection: a retrospective cohort study”

Marco Rossato, Angelo Di Vincenzo

Department of Medicine - DIMED, Clinica Medica 3, University Hospital of Padua, Italy

Key words: COVID-19, cigarette smoking, male, female, clinical outcome.

Correspondence to: Marco Rossato, Department of Medicine - DIMED, Clinica Medica 3, University Hospital of Padua, Via Giustiniani 2, 35128 Padua, Italy. Tel.: +39498218747. Fax: +39498213332. E-mail: marco.rossato@unipd.it

Dear Editor,

We have read with interest the recently published paper by Beronja *et al.* reporting the clinical outcomes in a group of patients hospitalized for COVID-19, being current smokers or not, and concluding that a history of cigarette smoking (past or active) is an independent factor for negative prognosis in COVID-19 patients [1]. Since the publication of the first data coming from China during the first months of the COVID-19 pandemic, it appeared clear that among hospitalized patients for COVID-19, those who were active smokers were less represented with respect to former and non-smokers, while one would have expected the opposite, being mainly previous smokers or never-smokers, those mainly hospitalized among SARS-CoV-2 infected subjects [2-4].

Those first and subsequent observations have led to the conclusion that cigarette smoke might contain a somehow “protective” factor (nicotine?) for the development of severe complications in SARS-CoV-2 infected subjects up to hospitalization [5-7].

At variance with these considerations, as also underlined by Beronja *et al.*, over the years, other studies have reported that cigarette smoking was associated with poorer clinical outcomes in COVID-19 patients [8].

The main observation regards the fact that the authors strongly underline that current smokers were more often admitted to the intensive care unit (ICU) than non-smokers, also showing a higher mortality rate [1]. This cannot be in conflict with the reported lower percentages of active smokers among hospitalized patients for COVID-19, since, although less represented among hospitalized subjects for COVID-19, once hospitalized, current smokers could have worse outcomes than non-active smokers [9]. On the other hand, it is well known that ICU admission is higher among smokers, whatever the cause of hospitalization [10], and thus the observations of the authors are probably expected also in COVID-19 patients, although there are data showing the opposite [11].

In this regard, the data of the authors also report a proportion of hospitalized patients with COVID-19 that is higher among non-active smokers than in current smokers (182/307 *vs.* 125/307, *i.e.*, 59.3% of non-active smokers *vs.* 40.7% of current smokers), although the authors did not highlight these data in their discussion [1].

What is important to consider is the difference between the percentages of current smokers and non-active smokers between

subjects hospitalized for COVID-19 and the percentages of those SARS-CoV-2 infected subjects that, once hospitalized, show a severe progression of the disease leading to ICU admission. The presence of multiple comorbidities prior to hospitalization for COVID-19 is thus a fundamental aspect to understand the outcomes of those patients [9].

Furthermore, the authors reported that the percentage of SARS-CoV-2 vaccinated patients among current smokers was half that of non-current smokers (8.8% *vs.* 16.6%), and maybe this could have favored the rise of clinical complications in non-vaccinated actively smoking patients, as also reported previously [12].

Finally, Beronja *et al.* reported that among hospitalized patients, the majority were females (68.7%). This result, also considering that in the authors’ country, female smokers are fewer than males [13], is quite different from what has been reported previously in all studies on COVID-19 hospitalized patients showing a higher prevalence of males among hospitalized patients with COVID-19 [14], but the reasons for such an unexpected higher female prevalence have not been fully elucidated by the authors [1].

The unhealthy effects of cigarette smoking are well known and do not need to be questioned further, and cigarette smoking should always be discouraged. Nonetheless, the data from epidemiological studies must push research to investigate, without any preconceived position, what the possible mechanisms are leading to the observed low prevalence of current smokers among hospitalized patients with COVID-19.

References

1. Beronja B, Karan A, Lukic B, et al. Smoking patterns and outcomes of severe SARS-CoV-2 infection: a retrospective cohort study. *Monaldi Arch Chest Dis* 2025. doi: 10.4081/monaldi.2025.2916.
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708-20.
3. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J* 2020;55:2000547.



4. Di Vincenzo A, Vettor R, Rossato M. COVID-19 and smoking habits: a smoky situation! *Monaldi Arch Chest Dis* 2020; 90:1539.
5. Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? *Intern Emerg Med* 2020;15:845-52.
6. Rossato M, Russo L, Mazzocut S, et al. Current smoking is not associated with COVID-19 *Eur Respir J* 2020;55:2001290.
7. Tolaj I, Baftiu N, Mustafa L, Fejza H. Smoking and COVID-19 in ICU Patients. *Med Arch* 2021;75:356-60.
8. Patanavanich R, Siripoon T, Amponnavarat S, Glantz SA. active smokers are at higher risk of COVID-19 death: a systematic review and meta-analysis. *Nicotine Tob Res* 2023;25: 177-84.
9. Emami A, Javanmardi F, Pirbonyeh N, et al. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. *Arch Acad Emerg Med* 2020;8:e35.
10. Klifto KM, Shetty PN, Slavin BR, et al. Impact of nicotine/smoking, alcohol, and illicit substance use on outcomes and complications of burn patients requiring hospital admission: systematic review and meta-analysis. *Burns* 2020; 46:1498-524.
11. Sharifi H, Fakharian A, Mirenayat MS, et al. The association of Smoking and SARS-CoV-2 Infection. *Tanaffos* 2024;23:83-9.
12. Piasecki TM, Smith SS, Baker TB, et al. Smoking status, nicotine medication, vaccination, and covid-19 hospital outcomes: findings from the COVID EHR cohort at the University of Wisconsin (CEC-UW) study. *Nicotine Tob Res* 2023;25:1184-93.
13. Tobacco Atlas. Country factsheet. Available from: <https://tobaccoatlas.org/factsheets/serbia>.
14. Rossato M, Di Vincenzo A, Andrisani A, et al. Re: “Sex and gender-related differences in covid-19 diagnoses and sars-cov-2 testing practices during the first wave of the pandemic: the dutch lifelines covid-19 cohort study” by Ballering et al. *J Womens Health* 2022;31:895-6.

Received: 17 February 2025; Accepted: 19 February 2025; Early view: 4 March 2025.

Contributions: both authors drafted the manuscript and critically reviewed the content of the manuscript.

Conflict of interest: the authors declare that they do not have potential conflicts of interest.

Ethics approval and consent to participate: not applicable.

Informed consent: not applicable.

Patient consent for publication: not applicable.

Availability of data and materials: not applicable.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

